Fimepinostat mesylate
Based on 15 publication(s) in Google Scholar
Fimepinostat mesylate potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes with an IC50 of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.
For research use only. We do not sell to patients.
- CAS No.: 1401998-36-4
- Formula: C24H28N8O7S2
- Molecular Weight:604.66
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Fimepinostat mesylate
More- J Clin Invest. 2025 Jun 2;135(11):e187490. [Abstract]
- J Exp Clin Cancer Res. 2020 Oct 17;39(1):219. [Abstract]
- Acta Pharmacol Sin. 2019 May;40(5):677-688. [Abstract]
- NPJ Precis Oncol. 2025 Nov 21;9(1):373. [Abstract]
- EMBO J. 2024 Nov;43(21):4954-4983. [Abstract]
- J Clin Endocrinol Metab. 2021 Jan 1;106(1):e232-e246. [Abstract]
- Chem Biol Interact. 2025 Sep 9:421:111735. [Abstract]
- Sci Rep. 2022 Apr 12;12(1):6090. [Abstract]
- Cancers (Basel). 2022 Feb 20;14(4):1067. [Abstract]
- Cancer Res Commun. 2023 Aug 17;3(8):1580-1593. [Abstract]
- ACS Med Chem Lett. 2015 Jun 22;6(8):948-52. [Abstract]
- Int J Parasitol Drugs Drug Resist. 2026 May 17;31:100649.
- bioRxiv. 2025 Aug 25.
- Research Square Print. 2023 Mar 9.
- SSRN. 2022 Nov 21.
-
Cell Proliferation/Viability Assay
-
WB
-
In Vivo Efficacy Study
-
IF
-
IHC
Biological Activity
Chemical Information
-
CAS No. 1401998-36-4
-
Molecular Weight 604.66
-
Formula C24H28N8O7S2
-
SMILES
O=C(C1=CN=C(N(CC2=CC3=NC(C4=CC=C(OC)N=C4)=NC(N5CCOCC5)=C3S2)C)N=C1)NO.CS(=O)(O)=O
-
Synonyms
CUDC-907 mesylate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (15)
-
Journal Impact Factor
-
Most Recent
-
J Clin Invest
2025 Jun 2;135(11):e187490. PMID: 40454483
Fimepinostat mesylate purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2025 Jun 2;135(11):e187490. [Abstract]
The indicated cell lines were treated with Fimepinostat , and cell viability was measured by CellTiter-Glo assays. IC50 values are shown.
Fimepinostat mesylate purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2025 Jun 2;135(11):e187490. [Abstract]
The indicated cell lines were treated with 5 nM Fimepinostat, 2 nM Romidepsin, or 500 nM Entinostat for 48 hours. The indicated proteins were measured by Western blot. Histone H3 serves as loading control.
Fimepinostat mesylate purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2025 Jun 2;135(11):e187490. [Abstract]
NSG mice were implanted with DNPC BCaP-1 PDXs and treated with vehicle, Fimepinostat (75 mg/kg orally, 5 times per week), or Romidepsin (1.5 mg/kg intraperitoneally, 2 times per week). Tumor volume (top) and mouse body weight (bottom) are shown.
-
J Exp Clin Cancer Res
The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer. [Abstract]2020 Oct 17;39(1):219. PMID: 33069237
Fimepinostat mesylate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2020 Oct 17;39(1):219. [Abstract]
DNA damage detected by comet assay in SCLC cells upon treatment with 10 nM CUDC-907 or 10 μM olaparib alone and in combination for 48 h.
Fimepinostat mesylate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2020 Oct 17;39(1):219. [Abstract]
Representative immunohistochemistry images of Ki67, cleaved-caspase3 (CC3), c-MYC, Rad51, and Ku80 on PDX tumors treated with CUDC-907 (75 mg/kg) and olaparib alone or in combination.
-
Acta Pharmacol Sin
CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression. [Abstract]2019 May;40(5):677-688. PMID: 30224636
Fimepinostat mesylate purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2019 May;40(5):677-688. [Abstract]
Aspc-1 and Capan-1 cells are collected for Western blotting with the indicated antibodies after treatment with CUDC-907 for 48 h.
-
NPJ Precis Oncol
Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study. [Abstract]2025 Nov 21;9(1):373. PMID: 41272086 -
EMBO J
Acetylation of TIR domains in the TLR4-Mal-MyD88 complex regulates immune responses in sepsis. [Abstract]2024 Nov;43(21):4954-4983. PMID: 39294473 -
J Clin Endocrinol Metab
2021 Jan 1;106(1):e232-e246. PMID: 33000123 -
Chem Biol Interact
CUDC-907 exerts an inhibitory effect on non-small cell lung cancer associated with induction of mitotic catastrophe and downregulation of YAP/TAZ signaling. [Abstract]2025 Sep 9:421:111735. PMID: 40935272 -
Sci Rep
QSAR analysis on a large and diverse set of potent phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using MLR and ANN methods. [Abstract]2022 Apr 12;12(1):6090. PMID: 35414065 -
Cancers (Basel)
2022 Feb 20;14(4):1067. PMID: 35205815 -
Cancer Res Commun
Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress. [Abstract]2023 Aug 17;3(8):1580-1593. PMID: 37599787 -
ACS Med Chem Lett
High-Throughput Screening of Patient-Derived Cultures Reveals Potential for Precision Medicine in Glioblastoma. [Abstract]2015 Jun 22;6(8):948-52. PMID: 26288699 -
-
-
-
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)